Program
ALN-SNCA
Its studies are mostly in Parkinson Disease, led by Regeneron Pharmaceuticals.
Furthest: phase 1, since Oct 9, 20251 company-led study, 1 open or runningNext primary completion: Jun 7, 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 11 open or running | phase 1since Oct 9, 2025 | Oct 9, 2025 | Jun 7, 2029phase 1 · NCT07216066 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 9, 2025First study: phase 1 study in Parkinson DiseaseFirst studyNCT07216066 · 46 planned · Canada, Netherlands
Ahead
- Jun 7, 2029Primary completion: phase 1 study in Parkinson DiseaseNCT07216066
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07216066Parkinson Disease · Canada, Netherlands | 1 | Recruiting | Jun 7, 2029 | 46 |
How it is read
Names in the registry
- “ALN-SNCA”, 1 entry
Conditions, from the studies’ own filings
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.